NCT04001803 - Study to Identify and Determine Best Implementation Practices for Injectable Cabotegravir+Rilpivirine in the United States (US) | Biotech Hunter

Enrollment

115

Participants

Timeline

Start Date

July 8, 2019

Primary Completion Date

October 5, 2020

Study Completion Date

March 18, 2022

Conditions

HIV Infections

Interventions

DRUG

CAB LA+RPV LA

Subjects will receive one tablet of CAB 30 milligram(mg) + RPV 25 mg once daily from Day 1 for 1 month. During month 1, subjects will receive 600 mg of CAB LA injection+ 900 mg of RPV LA injection. Following Month 1, subjects will receive 400mg of CAB LA + 600mg of RPV LA at each subsequent injection.

Trial Locations (9)

20017

GSK Investigational Site, Washington D.C.

30309

GSK Investigational Site, Atlanta

32209

GSK Investigational Site, Jacksonville

33140

GSK Investigational Site, Miami Beach

48072

GSK Investigational Site, Berkley

64111

GSK Investigational Site, Kansas City

75208

GSK Investigational Site, Dallas

95825

GSK Investigational Site, Sacramento

39216-4505

GSK Investigational Site, Jackson